Nurix officer Christine Ring plans $126K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. officer Christine Ring reported plans to sell 8,148 common shares, with an approximate sale date of April 2, 2026 and an aggregate market value of $126,131.04. The sale is reported under a Rule 10b5-1 plan adopted November 10, 2025; Morgan Stanley Smith Barney LLC is named as broker. The shares were acquired from the issuer as restricted stock units on May 2, 2022.
Ring's sales during the prior three months included 8,148 shares for gross proceeds of $125,792.90 on March 2, 2026; 8,148 shares for $135,757.90 and 6,113 shares for $101,860.92 on February 9, 2026; and 3,760 shares for $69,273.11 on January 20, 2026.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Restricted Stock Units financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Was Christine Ring's proposed NRIX sale under a 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.